Low Dose Aminoglutethimide Effectiveness in Breast Cancer
Author Information
Author(s): M. Dowsett, S.J. Santner, R.J. Santen, S.L. Jeffcoate, I.E. Smith
Primary Institution: Chelsea Hospital for Women
Hypothesis
Can low dose aminoglutethimide effectively inhibit peripheral aromatization in postmenopausal breast cancer patients?
Conclusion
Low dose aminoglutethimide significantly inhibits peripheral aromatase activity in postmenopausal breast cancer patients.
Supporting Evidence
- Low dose aminoglutethimide was shown to inhibit peripheral aromatase activity by 92%.
- The study involved measuring the activity of aromatase in vivo using radioactive injections.
- Previous studies indicated that higher doses of aminoglutethimide were less effective without glucocorticoids.
Takeaway
This study shows that a small amount of a medicine called aminoglutethimide can help stop the body from making certain hormones that can make breast cancer worse.
Methodology
Five postmenopausal breast cancer patients were treated with low dose aminoglutethimide, and their aromatase activity was measured using radioactive injections.
Limitations
The study had a small sample size and comparisons were made with previously published data, which may not be ideal.
Participant Demographics
Participants were postmenopausal breast cancer patients with varying previous treatments and responses.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website